Quantum Biopharma Ltd.
corporate_fare Company Profile
Quantum Biopharma Ltd. (NASDAQ:QNTM) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for QNTM at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-02, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for QNTM spans 6-K, 20-F.
Recent high-impact activity:
- Quantum BioPharma Moves to Voluntarily Delist from Canadian Securities Exchange
- Q2 2026 Results Extend Cash Runway to October 2027 as FDA Clears Lucid-MS Phase 2
- Quantum BioPharma Cuts Cash Burn 44%, Extends Runway to October 2027
- Quantum BioPharma Posts Q2 2026 Loss of $3.1M; GBB Trial Set for Aug 24
- FDA Clears Quantum BioPharma's Lucid-MS for Phase 2 Trial in Multiple Sclerosis
Dilution Risk
Low riskFiling-implied dilution signals for QNTM, detected from its recent SEC filings · based on capital-structure filings through 2026-05-06.
Significant Dilutive Capital Raises · Deteriorating Financial Position
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
QNTM files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.